Cargando…

Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study

Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bo, Yu, Yuanhang, Hubert, Shawna M., Zhang, Yue, Lu, Jianhua, Liu, Shihua, Xie, Fang, Zhao, Liang, Lei, Xiao, Deng, Wei, Chen, Jianying, Li, Yunqiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656194/
https://www.ncbi.nlm.nih.gov/pubmed/33192519
http://dx.doi.org/10.3389/fphar.2020.576994
_version_ 1783608331216093184
author Zhang, Bo
Yu, Yuanhang
Hubert, Shawna M.
Zhang, Yue
Lu, Jianhua
Liu, Shihua
Xie, Fang
Zhao, Liang
Lei, Xiao
Deng, Wei
Chen, Jianying
Li, Yunqiao
author_facet Zhang, Bo
Yu, Yuanhang
Hubert, Shawna M.
Zhang, Yue
Lu, Jianhua
Liu, Shihua
Xie, Fang
Zhao, Liang
Lei, Xiao
Deng, Wei
Chen, Jianying
Li, Yunqiao
author_sort Zhang, Bo
collection PubMed
description Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVID-19 are unknown. Methods: A multi-center, retrospective, cross-sectional study, based on five designated tertiary hospitals for the treatment of COVID-19 in Hubei Province, China. 112 cancer patients with COVID-19, and 105 COVID-19 patients without cancer were enrolled in the study between January 1st, 2020 and April 30th, 2020. The risk assessment of pro-inflammatory factors for disease severity and clinical adverse outcomes was identified by univariable and multivariable logistic regression models. Results: Of the 112 cancer patients with COVID-19, 40 (35.7%) patients were in critical condition and 18 (16.1%) patients died unfortunately. Univariate and multivariate analysis demonstrated that hemoglobin level and pro-inflammatory neutrophils and C-reactive protein (CRP), can be used as independent factors affecting the severity of COVID-19; Meanwhile, pro-inflammatory neutrophils and CRP can be used as an independent influencing factor for adverse clinical outcome of death. Moreover, the dynamic changes of neutrophils and CRP were also presented, and compared with COVID-19 patients without cancer, cancer patients with COVID-19 showed higher neutrophil counts and CRP levels. Conclusion: In cancer patients with COVID-19, the significant increase in pro-inflammatory neutrophils and CRP indicated a more critical illness and adverse clinical outcome, and pro-inflammatory neutrophils and CRP played a greater adverse role compare with COVID-19 patients without cancer, which may be the cause of critical illness and adverse clinical outcomes of cancer patients with COVID-19.
format Online
Article
Text
id pubmed-7656194
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76561942020-11-13 Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study Zhang, Bo Yu, Yuanhang Hubert, Shawna M. Zhang, Yue Lu, Jianhua Liu, Shihua Xie, Fang Zhao, Liang Lei, Xiao Deng, Wei Chen, Jianying Li, Yunqiao Front Pharmacol Pharmacology Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVID-19 are unknown. Methods: A multi-center, retrospective, cross-sectional study, based on five designated tertiary hospitals for the treatment of COVID-19 in Hubei Province, China. 112 cancer patients with COVID-19, and 105 COVID-19 patients without cancer were enrolled in the study between January 1st, 2020 and April 30th, 2020. The risk assessment of pro-inflammatory factors for disease severity and clinical adverse outcomes was identified by univariable and multivariable logistic regression models. Results: Of the 112 cancer patients with COVID-19, 40 (35.7%) patients were in critical condition and 18 (16.1%) patients died unfortunately. Univariate and multivariate analysis demonstrated that hemoglobin level and pro-inflammatory neutrophils and C-reactive protein (CRP), can be used as independent factors affecting the severity of COVID-19; Meanwhile, pro-inflammatory neutrophils and CRP can be used as an independent influencing factor for adverse clinical outcome of death. Moreover, the dynamic changes of neutrophils and CRP were also presented, and compared with COVID-19 patients without cancer, cancer patients with COVID-19 showed higher neutrophil counts and CRP levels. Conclusion: In cancer patients with COVID-19, the significant increase in pro-inflammatory neutrophils and CRP indicated a more critical illness and adverse clinical outcome, and pro-inflammatory neutrophils and CRP played a greater adverse role compare with COVID-19 patients without cancer, which may be the cause of critical illness and adverse clinical outcomes of cancer patients with COVID-19. Frontiers Media S.A. 2020-10-22 /pmc/articles/PMC7656194/ /pubmed/33192519 http://dx.doi.org/10.3389/fphar.2020.576994 Text en Copyright © 2020 Zhang, Yu, Herbet, Zhang, Lu, Liu, Xie, Zhao, Lei, Deng, Chen and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Bo
Yu, Yuanhang
Hubert, Shawna M.
Zhang, Yue
Lu, Jianhua
Liu, Shihua
Xie, Fang
Zhao, Liang
Lei, Xiao
Deng, Wei
Chen, Jianying
Li, Yunqiao
Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
title Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
title_full Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
title_fullStr Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
title_full_unstemmed Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
title_short Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
title_sort prognostic value of pro-inflammatory neutrophils and c-reactive protein in cancer patient with coronavirus disease 2019: a multi-center, retrospective study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656194/
https://www.ncbi.nlm.nih.gov/pubmed/33192519
http://dx.doi.org/10.3389/fphar.2020.576994
work_keys_str_mv AT zhangbo prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT yuyuanhang prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT hubertshawnam prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT zhangyue prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT lujianhua prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT liushihua prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT xiefang prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT zhaoliang prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT leixiao prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT dengwei prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT chenjianying prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy
AT liyunqiao prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy